Johnson & Johnson 3Q Revenues: $19.7 billion (+10%) 3Q Earnings: $3.8 billion (-12%) YTD Revenues: $56.3 billion (+5%) YTD Earnings: $12.0 billion (-6%) Comments: Worldwide Pharmaceutical sales were $9.7 billion in the quarter, up 15%. Domestic sales increased 15% and international sales increased 16%. Remicade sales were $1.6 billion in the quarter, down 8%. Strong growth in new products include DARZALEX ($317 million, up 95%), for the treatment of patients with multiple myeloma and IM...